Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 4/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 8/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326120 | 0.88 | NLRP3 (0.50) | IL1BHDAC4HDAC6SYKNLRP3 | |
| SCHEMBL29326175 | 0.87 | SYK (0.40) | IL1BHDAC4HDAC6SYKNLRP3 | |
| SCHEMBL29326172 | 0.86 | SYK (0.39) | IL1BHDAC4HDAC6TAS1R3TAS1R1 | |
| SCHEMBL29326443 | 0.85 | NLRP3 (0.52) | IL1BTAS1R3TAS1R1TAS1R2NLRP3 | |
| SCHEMBL30684765 | 0.85 | NLRP3 (0.52) | IL1BTAS1R3TAS1R1TAS1R2NLRP3 | |
| SCHEMBL29326833 | 0.84 | IL1B (0.47) | IL1BSYKNLRP3KCNH2GABBR2 | |
| SCHEMBL29326561 | 0.77 | IL1B (0.52) | IL1BNLRP3KCNH2GABBR2GABBR1 | |
| SCHEMBL27182195 | 0.76 | NLRP3 (0.55) | IL1BTAS1R3TAS1R1TAS1R2NLRP3 | |
| SCHEMBL29326460 | 0.76 | IL1B (0.44) | IL1BNLRP3KCNH2 | |
| SCHEMBL29326647 | 0.76 | IL1B (0.51) | IL1BNLRP3KCNH2GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | IL1B 11/4885HDAC4 411/4885HDAC6 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.